First zero contrast PCI guided by intracoronary ultrasound in the Czech Republic
Authors:
Marek Sůva 1,2; Roman Štípal 1,2; Martin Poloczek 1,2; Jan Kaňovský 1,2; Otakar Boček 1; Petr Jeřábek 1; Martin Hudec 1,2; Vojtěch Brázdil 1,2; Petr Kala 1,2
Authors‘ workplace:
Fakultní nemocnice Brno
1; Lékařská fakulta Masarykovy Univerzity, Brno
2
Published in:
Vnitř Lék 2021; 67(7): 433-437
Category:
Case reports
Overview
Contrast induced nephropathy is associated with worse clinical outcome in patients undergoing coronary intervention. The most profound risk factor is advanced chronic renal insufficiency. Due to the increasing number of coronary interventions on severally ill patients, there is a need of modern therapeutic approach that could reduce the volume of contrast media to minimum or even zero. Herein, the authors present a case report of a 68-year-old patient with chronic kidney disease, who required elective coronary intervention (PCI) due to a significant lesion of the left anterior descending coronary artery. During this intervention, maximum emphasis was given on reduction of contrast media. To the best of our knowledge, this was the first similar intervention performed in the Czech Republic. Minimum contrast PCI guided by the intracoronary ultrasound, i.e. the IVUS-guided zero-contrast PCI may serve as a potential alternative to standard, angiography-guided PCI.
Keywords:
acute kidney injury – ultralow contrast PCI – contrast induced nephropathy – IVUS‑guided PCI – chronic kidney insufficiency
Sources
1. Nash K, Hafeez A, Hou S. Hospital‑acquired renal insufficiency. Am J Kidney, DiS. 2002.
2. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute Dialysis Quality Initiative workgroup. Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care [Internet]. Srpen 2004; 8(4): R204–R212. Dostupné z: http://www.ncbi.nlm.nih.gov/pubmed/15312219
3. Thomsen HS, Morcos SK. Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) guidelines. British Journal of Radiology. 2003.
4. Mehran R, Dangas GD, Weisbord SD. Contrast‑Associated Acute Kidney Injury. Ingelfinger JR, editor. N Engl J Med [Internet]. 30. květen 2019; 380(22): 2146–2155. Dostupné z: http://www.nejm.org/doi/10.1056/NEJMra1805256
5. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M et al. A simple risk score for prediction of contrast‑induced nephropathy after percutaneous coronary intervention. J Am Coll Cardiol [Internet]. Říjen 2004; 44(7): 1393–1399. Dostupné z: https://linkinghub. elsevier.com/retrieve/pii/S0735109704014457
6. Neumann FJ, Sousa‑Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal 2019.
7. Victor S, Sankardas MA. Contrast Induced Nephropathy – An update. e‑journal ESC Counc Cardiol Pract Vol13 No4. 2014.
8. de Laforcade L, Bobot M, Bellin M‑F, Clément O, Grangé S, Grenier N et al. c. Diagn Interv Imaging [Internet]. Březen 2021; 102(3): 131–139. Dostupné z: https://linkinghub.elsevier. com/retrieve/pii/S2211568421000280
9. Berwanger O. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: Main results from the randomized acetylcysteine for contrast‑induced nephropathy trial (ACT). Circulation. 2011
10. Weisbord SD, Gallagher M, Jneid H, Garcia S, Cass A, Thwin S‑S et al. Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine. N Engl J Med. 2018.
11. Leoncini M, Toso A, Maioli M, Tropeano F, Villani S, Bellandi F. Early high‑dose rosuvastatin for contrast‑induced nephropathy prevention in acute coronary syndrome: Results from the PRATO‑ACS study (protective effect of rosuvastatin and antiplatelet therapy on contrast‑induced acute kidney injury and myocardial damage. J Am Coll Cardiol. 2014.
12. Jo S‑H, Koo B‑K, Park J‑S, Kang H‑J, Cho Y‑S, Kim Y‑J et al. Prevention of radiocontrast medium–induced nephropathy using short‑term high‑dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial a randomized controlled study. Am Heart J [Internet]. Březen 2008; 155(3): 499.e1–499.e8. Dostupné z: https://linkinghub.elsevier.com/retrieve/pii/S0002870307010393
13. Kawashima S, Takano H, Iino Y, Takayama M, Takano T. Prophylactic Hemodialysis Does Not Prevent Contrast‑Induced Nephropathy After Cardiac Catheterization in Patients With Chronic Renal Insufficiency. Circ J [Internet]. 2006; 70(5): 553–558. Dostupné z: http://www.jstage.jst.go.jp/article/circj/70/5/70_5_553/_article
14. Ali ZA, Karimi Galougahi K, Nazif T, Maehara A, Hardy MA, Cohen DJ et al. Imagingand physiology‑guided percutaneous coronary intervention without contrast administration in advanced renal failure: a feasibility, safety, and outcome study. Eur Heart J [Internet]. 21. říjen 2016; 37(40): 3090–3095. Dostupné z: https://academic.oup.com/ eurheartj/article‑lookup/ doi/10.1093/eurheartj/ehw078
15. Rozenbaum Z, Benchetrit S, Rozenbaum E, Neumark E, Mosseri M, Pereg D. Ultra‑Low Contrast Volume for Patients with Advanced Chronic Kidney Disease Undergoing Coronary Procedures. Nephron 2018.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2021 Issue 7
Most read in this issue
- Appropriate and inappropriate therapies of implantable cardioverter‑defibrillators
- Hereditary hemorrhagic telangiectasia (Osler‑Weber‑Rendu syndrome) – Part II. Pharmacological therapy and international guidelines for the therapy 2020
- In general medicine surplus of care can harm the patients
- Metabolic and endocrine diseases – is our approach always rational?